期刊文献+

微生态制剂防治新生儿坏死性小肠结肠炎病例对照研究 被引量:12

Role of probiotics in the prevention of neonatal necrotizing enterocolitis: a case-control study
下载PDF
导出
摘要 目的探讨新生儿坏死性小肠结肠炎(NEC)的危险因素及应用微生态制剂(培菲康)预防NEC发生的有效性。方法对2002年1月至2005年5月住院治疗的2528例新生儿分为微生态制剂预防组与非预防组,观察两组NEC的发病率;以确诊NEC的患儿为病例组,非NEC新生儿为对照组进行病例对照研究。结果预防组1182例中6例诊断为NEC,发病率0.51%;非预防组1346例中19例发生NEC,发病率为1.41%,两组差异具有显著性(P<0.05)。条件Logistic回归分析提示:胎龄、新生儿缺氧缺血性脑病、败血症及病情危重程度是危险因素;微生态制剂的应用是保护因素。结论避免NEC的危险因素,预防性应用微生态制剂能够降低NEC发病率。 Objective To assess the role of probiotics in the prevention of neonatal necrotizing enteroeolitis (NEC) and to investigate the risk factors for NEC. Methods A total of 2 528 hospitalized neonates between January 2002 and May 2005 were assigned into either receiving prophylactic use of probiotics bifoco ( Prevention group, n = 1 182) or without probioties supplementation (Control group, n = 1 346). The incidence of NEC was compared between the two groups. The risk factors for NEC were investigated by conditional logistic regression muhifaetorial analysis. Results There were 19 cases of NEC in the Control group ( 1.41% ) , but only 6 cases in the Prevention group (0.51% ) ( P 〈 0.05 ). Gestational age ( OR = 5. 521 ) , hypoxie-isehemic encephalopathy ( OR = 3. 887 ) , specticemia ( OR = 4. 854 ) and critical illness scores ( OR = 5. 989) were the risk factors for NEC, while the prophylactic use of probioties was an independent protective factor for NEC ( OR = 0. 255). Conclusions The prophylactic use of probiotics may reduce the incidence of NEC in neonates .
出处 《中国当代儿科杂志》 CAS CSCD 2006年第6期464-466,共3页 Chinese Journal of Contemporary Pediatrics
关键词 坏死性小肠结肠炎 微生态制剂 危险因素 新生儿 Necrotizing enterocolitis Probiotics Risk factor Neonate
  • 相关文献

参考文献10

二级参考文献11

  • 1Benno Y,Sawada K,Mrrsnoda T.The intestinal microflora of infants:conposition of fecal flora in breast-fed and bottle-fed in fants[J].Microbiol Immunol,1984,28(9):975. 被引量:1
  • 2Sakate H,Yoshioka H,Fujitak.Development of the intestinal flora in very low birth weight infants compared to normal full-trem newborns[J].Pediatrics,1985,76(2):186. 被引量:1
  • 3Barnard J. Epidermal growth factor receptor blockade: an emerging therapeutic modality in gastroenterology[J]. Gastroenterology, 2001,120(7):1872-1874. 被引量:1
  • 4Huang FS, Kemp CJ, Williams JL, Erwin CR, Warner BW. Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury[J]. Am J Physiol Gastrointest Liver Physiol, 2002,282(3):G432-442. 被引量:1
  • 5Ichiba H, Fujimura M, Takeechi T. Levels of epidermal growth factor in human cord blood[J]. Biol Neonate, 1992,61(5):302-307. 被引量:1
  • 6Miettinen PJ.Epidermal growth factor receptor in mice and men -any applications to clinical practice[J]. Ann Med,1997,29(6):531-534. 被引量:1
  • 7Fagbemi AO, Wright N, Lakhoo K, Edwards AD. Immunoreactive epidermal growth factor receptors are present in gastrointestinal epithelial cells of preterm infants with necrotising enterocolitis[J]. Early Hum Dev,2001,65(1):1-9. 被引量:1
  • 8Dvorak B, Halpern MD, Holubec H, Williams CS, McWilliam DL, Dominguez JA,et al. Epidermal growth factor reduces the development of necrotizing enterocolitis in a neonatal rat model[J]. Am J Physiol Gastrointest Liver Physiol,2002,282(1):G156-164. 被引量:1
  • 9Sullivan PB, Brueton MJ,Tabara ZB, Goodlad RA, Lee CY, Wri-ght NA.Epidermal growth factor in necrotising enteritis[J]. Lancet, 1991,338(8758):53-54. 被引量:1
  • 10张琳,粱庆红.新生儿肠道微生态学研究现况[J].中国实用儿科杂志,2000,15(12):761-762. 被引量:32

共引文献345

同被引文献152

引证文献12

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部